Self-adjusting gastric band having various compliant components and/or a satiety booster

Information

  • Patent Grant
  • 9295573
  • Patent Number
    9,295,573
  • Date Filed
    Wednesday, July 3, 2013
    11 years ago
  • Date Issued
    Tuesday, March 29, 2016
    8 years ago
Abstract
In some embodiments, the present invention generally provides self-adjusting gastric banding systems for the treatment of obesity and obesity related conditions, as well as systems for allowing the automatic self-adjustment of gastric bands when a patient swallows a large bolus. In some embodiments, the present invention generally provides for gastric banding systems having a satiety booster, for example, to increase satiety levels when a patient desires to curb appetite at a particular time. In some embodiments, the present invention may provide for gastric banding systems that allow for both the automatic self-adjustment of gastric bands when a patient swallows a large bolus and an incorporated satiety booster for increasing satiety levels when a patient desires to curb appetite at a particular time.
Description
FIELD

The present invention generally relates to medical systems and apparatus and uses thereof for treating obesity and/or obesity-related diseases, and more specifically, relates to gastric banding systems that self-adjust to changes in a patient and/or provides a satiety booster.


BACKGROUND

Adjustable gastric banding apparatus have provided an effective and substantially less invasive alternative to gastric bypass surgery and other conventional surgical weight loss procedures. Despite the positive outcomes of invasive weight loss procedures, such as gastric bypass surgery, it has been recognized that sustained weight loss can be achieved through a laparoscopically-placed gastric band, for example, the LAP-BAND® (Allergan, Inc., Irvine, Calif.) gastric band or the LAP-BAND APO (Allergan, Inc., Irvine, Calif.) gastric band. Generally, gastric bands are placed about the cardia, or upper portion, of a patient's stomach forming a stoma that restricts food's passage into a lower portion of the stomach. When the stoma is of an appropriate size that is restricted by a gastric band, food held in the upper portion of the stomach may provide a feeling of satiety or fullness that discourages overeating. Unlike gastric bypass procedures, gastric band apparatus are reversible and require no permanent modification to the gastrointestinal tract. An example of a gastric banding system is disclosed in Roslin, et al., U.S. Patent Pub. No. 2006/0235448, the entire disclosure of which is incorporated herein by this specific reference.


Over time, a stoma created by a gastric band may need adjustment in order to maintain an appropriate size, which is neither too restrictive nor too passive. Accordingly, prior art gastric band systems provide a subcutaneous fluid access port connected to an expandable or inflatable portion of the gastric band. By adding fluid to or removing fluid from the inflatable portion by means of a hypodermic needle inserted into the access port, the effective size of the gastric band can be adjusted to provide a tighter or looser constriction.


Sometimes, adjustment of a gastric band may be desirable in between adjustments made by a physician. For example, during normal operation of the gastric band, the band applies pressure to the outer surface of the upper stomach. But in some instances, the patient may swallow a bolus that is too large to pass through the constriction produced by the band. The result can be a painful experience which, if it persists, may require medical intervention to release the blockage.


Some attempts have been made to account for this possibility of blockage. For example, with reference to FIG. 1A, Coe, et al., U.S. Patent Pub. No. 2009/0216255 discloses a flow control device A that moves fluid between a hydraulic restriction system and a fluid source B. The additional flow control device A controls a rate of fluid flow between the restriction device and the fluid source B. With reference to FIG. 1B, Coe, et al., European Patent Application No. 2 074 970 A1 discloses a separate restriction device and pressure adjustment device C. The pressure adjustment device C regulates a constant force applied by the restriction device using, for example, a bellows and a spring.


With reference to FIG. 1C, Lechner, U.S. Patent Pub. No. 2009/0054914 discloses a controllable stomach band that has a chamber for controlling restriction of the stomach band. The chamber is coupled to a separate pressure chamber D that receives fluid leaving the chamber in the stomach band. The pressure chamber D is separated from the esophageal-gastric junction of the patient's stomach.


With reference to FIG. 2, Forsell, U.S. Patent Pub. No. 2004/0064110 discloses an injection port E which can be pressed to change the volume in the gastric band.


With reference to FIG. 3, Steffen, U.S. Patent Pub. No. 2009/0062826 discloses an adjustable gastric band with a “conveyance device” that is powered by a “power storage device.” The power storage device operates the conveyance device to move fluid between expandable chambers to adjust the gastric band.


Accordingly, in certain embodiments, it may be desirable to develop a self-adjusting gastric band that will provide the needed pressure to the stomach to create the stoma and facilitate weight control, but that will also adapt and open up to allow a large bolus to pass through. Additionally, it may be desirable to make the adjustments without additional, complicated fluid control mechanisms, flow rate limiting devices, and/or valves to regulate the transfer of fluid within the self-adjusting gastric band. Moreover, it is desirable to make these adjustments to the gastric band utilizing compliant components to both reduce and restore the constriction of the gastric band.


Accordingly, in certain embodiments, it is desirable to develop a gastric band having a bladder that a patient may press to obtain a satiety boost.


SUMMARY

Generally described herein are certain embodiments directed to automatic, self-adjusting, gastric banding systems that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. The apparatus and systems described herein in these certain embodiments aid in facilitating obesity control and/or treating obesity-related diseases while being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein may be automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and/or location changes.


In one embodiment, a self-adjusting gastric band automatically adjusts to allow a large bolus of food to pass through a constriction in the patient's stomach formed by the gastric band. The gastric band comprises an inflatable portion that is disposable about an esophageal-gastric junction of the patient. The gastric band also comprises an access port fluidly coupled to the inflatable portion via tubing to fill and drain the inflatable portion.


Further, the gastric band comprises a first compliant portion coupled to a part of the system. For example, the first compliant portion may be coupled to the inflatable portion, the access port, and/or the tubing. The first compliant portion automatically relaxes the constriction formed by the self-adjusting gastric band and allows the large bolus to pass through the constriction. After the bolus passes through the constriction, the gastric band automatically returns to its previous state.


In accordance with various embodiments, the first compliant portion facilitates automatically relaxing the constriction formed by the self-adjusting gastric band without causing a fluid to exit the inflatable portion of the gastric band. For example, the self-adjusting gastric band may comprise a ring coupled to the inflatable portion of the gastric band. The ring provides structure and support to the inflatable portion, and the ring facilitates disposing the inflatable portion about the esophageal-gastric junction.


The ring may be a flexible ring with a diameter that expands when a predetermined pressure is generated in the inflatable portion. For example, the predetermined pressure may be generated in response to the large bolus passing through the esophageal-gastric junction. The flexible ring expands to automatically relax the constriction formed by the self-adjusting gastric band. In various embodiments, the ring has a durometer in the range of approximately 20 to approximately 70.


According to a further embodiment, the first compliant portion receives a first amount of fluid from the inflatable portion when the large bolus causes a pressure in the first compliant portion to exceed an expansion pressure. Receiving the first amount of fluid from the inflatable portion facilitates relaxing the constriction formed by the self-adjusting gastric band and allowing the large bolus to pass through the constriction.


In an embodiment, the first compliant portion is fluidly coupled to the inflatable portion. The first compliant portion facilitates removing the first amount of fluid from the inflatable portion when the large bolus passes through the constriction.


According to another embodiment, the self-adjusting gastric band further comprises a second compliant portion fluidly coupled to the access port. The second compliant portion automatically removes a second amount of fluid from the inflatable portion via the access port to facilitate relaxing the constriction formed by the inflatable portion.


The tubing of the gastric banding system may be compliant tubing that expands in response to a pressure in the tubing exceeding a tubing expansion pressure when the large bolus passes through the constriction formed by the self-adjusting gastric band. In this regard, a third amount of fluid is removed from the inflatable portion when the compliant tubing expands. The tubing may be perforated to facilitate receiving the fluid from the inflatable portion via the tubing.


Furthermore, another embodiment of the self-adjusting gastric band comprises a third compliant portion fluidly coupled to the tubing for automatically receiving a third amount of fluid from the inflatable portion via the tubing when the large bolus enters the esophageal-gastric junction. Receiving the third amount of fluid from the inflatable portion facilitates relaxing the constriction formed by the gastric band and allowing the large bolus to pass through the constriction.


The compliant components, according to various embodiments, comprise a kink-resisting feature. Further, the compliant components may comprise a leak-resisting feature. These components may be an elastic polymer, a balloon, a rubber container, a silicone container, a collapsible container, a bellows, and combinations thereof.


Generally described herein are certain embodiments directed to satiety boosting bladders which may transfer fluid from the bladder to inflatable portions of a gastric band, thereby tightening the gastric band and providing the patient a “satiety boost”. After a period of time, the fluid may return from the gastric band back to the satiety boosting bladder.


In one embodiment, the satiety boosting bladder may be designed to allow for the free flow of fluids in and out of the gastric banding system without requiring valves and without the need to interface with an injection needle. The satiety boosting bladder may allow for intentional fluid transfer when the patient consciously presses on the bladder (by pressing on the skin area near the bladder).


In one embodiment, a gastric band system may include a satiety boosting bladder located in fluid connection between the gastric band and an access port. The satiety boosting bladder may be physically located beneath the skin of a patient but above the rectus muscle fascia such that the patient may induce pressure on the bladder and disperse fluid to the gastric band by pressing on the skin area closest to the location of the bladder.


In one embodiment, the satiety boosting bladder may be fluidly coupled to one end of an access port, wherein the access port may be located between the satiety boosting bladder and a tube coupling the access port to a gastric band.


In one embodiment, the satiety boosting bladder may be spherically shaped, rectangularly shaped, or circularly shaped. Additionally, and/or alternatively, the satiety boosting bladder may have non-uniform, tapered walls.


In one embodiment, the satiety boosting bladder may be a series of cylindrical components or a coiled component.


In one embodiment, the satiety boosting bladder may include flow restriction or flow controlling components such as a flow restrictor and/or a valve.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates a prior art system that includes a flow rate limiting device.



FIG. 1B illustrates a prior art system that includes a fluid control mechanism.



FIG. 1C illustrates a prior art system that includes a valve and a chamber separated from the esophageal-gastric junction.



FIG. 2 illustrates a prior art system with a pressable injection port.



FIG. 3 illustrates a prior art system with a gastric banding system that is immune to deliberate influence by a patient.



FIG. 4 illustrates an exploded, perspective view of a self-adjusting gastric banding system according to an embodiment of the present invention.



FIG. 5 illustrates an exploded, perspective view of a self-adjusting gastric banding system having various compliant components according to an embodiment of the present invention.



FIG. 6 illustrates an exploded, perspective view of another self-adjusting gastric banding system having various compliant components according to an embodiment of the present invention.



FIG. 7 illustrates a chart showing pressure-volume curves for a standard gastric band and a self-adjusting gastric band according to an embodiment of the present invention.



FIG. 8 illustrates a chart showing pressure-time curves for a standard gastric band and a self-adjusting gastric band subject to a period of obstruction according to an embodiment of the present invention.



FIG. 9 illustrates a gastric banding system with a satiety boosting bladder according to an embodiment of the present invention.



FIG. 10 illustrates an exploded, perspective view of a gastric banding system having a satiety boosting bladder according to an embodiment of the present invention.



FIG. 11 illustrates an exploded, perspective view of another gastric banding system having a satiety boosting bladder according to an embodiment of the present invention.



FIG. 12 illustrates an exploded, perspective view of a gastric banding system having a “T-connected” satiety boosting bladder according to an embodiment of the present invention.



FIG. 13 illustrates a circular satiety boosting bladder according to an embodiment of the present invention.



FIG. 14 illustrates a rectangular satiety boosting bladder according to an embodiment of the present invention.



FIG. 15 illustrates a series of cylindrical bladders according to an embodiment of the present invention.



FIG. 16 illustrates a series of differently sized cylindrical bladders according to an embodiment of the present invention.



FIG. 17 illustrates a coiled bladder according to an embodiment of the present invention.



FIG. 18 illustrates a cross-sectional view of a satiety boosting bladder according to an embodiment of the present invention.



FIG. 19 illustrates a bladder having a flow control mechanism according to an embodiment of the present invention.



FIG. 19A illustrates a close up view of the flow control mechanism of FIG. 19 according to an embodiment of the present invention.





DETAILED DESCRIPTION

The present invention generally provides self-adjusting gastric banding systems, for example, for treatment of obesity and obesity related conditions, as well as systems for allowing automatic self-adjustment of gastric bands when a patient swallows a large bolus.


Self-adjusting gastric bands are effective in helping a patient lose weight when the band is properly tightened around the patient's esophageal-gastric junction. During normal operation, the gastric band applies pressure to the outer surface of the upper stomach. But, in some instances, the patient may swallow a bolus which is too large to pass through the constriction produced by the gastric band—for example, when the patient swallows a large piece of steak. The result can be a painful experience which, if it persists, may require medical intervention to release the blockage.


In accordance with various embodiments of the present invention, the self-adjusting gastric band provides the needed pressure to the stomach to encourage weight loss. However, when a large bolus of food is swallowed, the self-adjusting gastric band temporarily and automatically opens up to allow the bolus through. After the bolus passes through, the mechanisms within the gastric band return the gastric band to its original size and shape. In an embodiment, electrical power and/or power external to the patient is not utilized to perform these adjustments. Further, in an embodiment, complicated fluid control mechanisms, flow rate limiting devices, and/or valves are not utilized to regulate the transfer of fluid within the self-adjusting gastric band.


Turning now to FIG. 4, a self-adjusting gastric banding system 400 comprises a gastric band 405 coupled to a subcutaneous injection port 435 via tubing 403. The gastric band 405 comprises a circular ring 407 and an inflatable portion 410 disposed on the inside of the ring 407. The inflatable portion 410 separates the patient's stomach from the ring 407 when the gastric band 405 is implanted around the esophageal-gastric junction of the patient's stomach. The ring 407 provides structure and support to the inflatable portion 410, and facilitates implanting the gastric band 405 around the patient's stomach.


The access port 435 may be sutured onto the rectus muscle sheath or any other conveniently accessible muscle. The rectus muscle sheath provides a secure surface on which to attach the access port 435 under a layer of fat that separates the patient's skin from the muscle.


The inflatable portion 410 may be filled and drained with a fluid via the tubing 403. For example, the tubing 403 may be connected to the subcutaneous access port 435 for filling and draining the inflatable portion 410 via subcutaneous injections. The inflatable portion 410 may also be coupled to a reservoir to facilitate automatic adjustment of the inflatable portion 410, and the constriction it causes, when a large bolus attempts to pass through the constriction. When more fluid is introduced in the inflatable portion 410, the constriction around the stomach generally becomes tighter. Correspondingly, when less fluid is present, the constriction loosens and/or opens up.


The fluids used within the gastric band 405 may include any fluid that is biocompatible and incompressible. The fluid has no adverse effect on the patient in the unlikely event that a leak emanates from the system. The fluid can simply be water or any biocompatible polymer oil such as caster oil. In an example embodiment, the fluid is saline, a drug, and/or combinations thereof.


In an embodiment, the ring 407 is designed to be a compliant portion of the gastric band 405. For example, the ring 407 may flex and/or expand in response to a bolus of food moving through the constriction caused by the gastric band 405. The ring 407 may have flexible components and rigid components, such that the flexible components expand when a certain elevated and/or maximum pressure is reached in the inflatable portion 410. This elevated pressure may exist due to the presence of an obstruction such as a bolus near the gastric band 405. As the ring 407 expands, the diameters of the ring 407 and the inflatable portion 410 increase, and the constriction on the stomach due to the gastric band 405 is reduced to allow the bolus to pass through. When the bolus has passed, the elevated pressure no longer exists, and the gastric band 405 returns to the pre-obstruction state.


In another embodiment, the entire ring 407 may be flexible and/or expandable such that a diameter of the ring 407 increases in response to the elevated pressure in the inflatable portion 410. For example, the ring 407 may be constructed of silicone that has a durometer in the range of approximately 20 to approximately 70.


It should be understood that the flexible ring 407 and the other mechanisms disclosed herein for automatically adjusting the constriction of the gastric band 405 are only example embodiments. Any mechanism for automatically adjusting the constriction of the gastric band 405 that does not include electrical power, power external to the patient, complicated fluid control mechanisms, flow rate limiting devices, and/or valves is contemplated within the scope of the present invention.


Furthermore, although various compliant components are illustrated in each of the figures, it should be understood that any combination of the various compliant components may be utilized in different embodiments. For example, an embodiment may include one compliant component—only the ring, the tubing, or the access port may be compliant. In other embodiments, any combination of the ring, the tubing, and the access port may be compliant. For example, an embodiment may include a compliant ring and a compliant port, an embodiment may include compliant tubing and a compliant port, or an embodiment may include a compliant ring and compliant tubing. Any combination of compliant components is contemplated within the scope of the present invention.


With reference to FIG. 5, various compliant components may be utilized to automatically adjust the constriction of the gastric band 505 about the esophageal-gastric junction of the patient's stomach. Although three compliant components are illustrated in FIG. 5, as noted above, one or more of the components may be present in various embodiments of the present invention.


For example, in an embodiment, a band compliant component 512 is fluidly coupled to the inflatable portion 510 of the gastric band 505. The compliant component 512 is located on the outside of the ring 507, opposite the inflatable portion, and may be coupled to the ring 507 and the inflatable portion. Further, in an embodiment, one or more fluid ports may extend from the inflatable portion 510 to the compliant component 512 to fluidly couple the inflatable portion 510 to the compliant component 512.


With reference to FIGS. 5 and 6, and in accordance with various embodiments, a tube compliant component 514, 614 may be fluidly coupled to the tubing 503, 603. As illustrated in FIG. 6, the compliant component 614 may run along substantially the entire length of the tubing 603. In another embodiment, as illustrated in FIG. 5, the compliant component 514 may be limited to a smaller section of the entire length of the tubing 503. The compliant component 514, 614 may be fluidly coupled to the tubing 503 at one or more locations. For example, with reference to FIG. 6, the compliant component 614 and the tubing 603 may be perforated to allow for efficient transfer of the fluid between the tubing 603 and the compliant component 614.


In another embodiment, the tubing 603 itself may be compliant, and the durometer, thickness, and/or diameter of the tubing 603 may be altered to achieve a desired degree of compliance. Other components of the gastric band 605 may similarly have altered properties in order to achieve a desired degree of compliance.


In an embodiment, where the tube compliant component 514, 614 facilitates automated adjustment of the gastric band 505, 605, the compliant component 514, 614 may have features configured to resist kinking and/or leakage of the tubing 503, 603. For example, the compliant component 514, 614 may include rigid portions (e.g., similar to a skeleton) and flexible portions. The rigid components may give structure to the compliant component 514, 614 and/or the tubing 503, 603 to prevent kinking and/or leakage due to external forces on the compliant component 514, 614 and/or the tubing 503, 603. The flexible components may automatically expand in response to an increased pressure in the inflatable portion 510, 610 of the gastric band 505, 605.


In accordance with another embodiment, and with continued reference to FIGS. 5 and 6, the access port 535, 635 may be fluidly coupled to a port compliant component 516, 616. As illustrated in FIG. 5, the compliant component 516 may be a balloon, reservoir, or other expandable device that is adjacent to the port 535. In an embodiment as illustrated in FIG. 6, the compliant component 616 may substantially surround the access port 635. The compliant component 616 may be fluidly coupled to the access port 635 at a single location near a coupling between the tubing 603 and the access port 635. In another embodiment, the compliant component 616 may be fluidly coupled to the access port 635 at multiple locations.


As noted above, any combination of the inflatable portion 510, 610, the compliant component 512, the compliant ring 407, the tube compliant component 514, 614, and/or the port compliant component 516, 616 may be used in accordance with various embodiments. When the pressure in the inflatable portion 510, 610 exceeds a predetermined pressure, the compliant components 407, 512, 514, 516, 614, 616, in any particular configuration or combination, expand to receive an amount of the fluid from the inflatable portion 510, 610 via the inflatable portion 510, 610, the tubing 503, 603, and/or the access port 535, 635, and/or to reduce the constriction formed by the gastric band 405, 505, 605. The predetermined pressure may be predetermined based on a pressure that would indicate an obstruction is attempting to pass through the constriction caused by the gastric band 405, 505, 605.


The compliant components 407, 512, 514, 516, 614, 616 described herein, in accordance with various embodiments, may be designed with an expansion pressure at which pressure the components 407, 512, 514, 516, 614, 616 begin to expand, to receive fluid from the inflatable portion 510, 610 of the gastric band 505, 605, and/or to reduce the constriction formed by the gastric band 405, 505, 605. The expansion pressure may be configured to correspond to a predetermined pressure in the inflatable portion 410, 510, 610 that may indicate an obstruction exists in the esophageal-gastric junction.


For example, the obstruction may result in a large spike in intra-esophageal pressure that exceeds the expansion pressure and causes the compliant components to expand and receive fluid from the inflatable portion 510, 610. The reduction in fluid in the inflatable portion 510, 610 causes the constriction around the patient's stomach to loosen, in order to relieve the spike in pressure and allow the obstruction to pass through the esophageal-gastric junction. When the obstruction passes, the increased pressure in the inflatable portion 510, 610 is reduced, and the fluid flows back into the inflatable portion 510, 610 due to the elasticity of the compliant components 512, 514, 516, 614, 616, to restore the original amount of constriction of the gastric band 505, 605. This change in constriction of the gastric band 505, 605 results or is achieved without the use of flow rate limiting devices or valves.


The graph in FIG. 7 illustrates, according to various embodiments, the effect the compliant components described herein have on the pressure in the gastric banding system. As can be seen in FIG. 7, a standard gastric banding system without compliant components has a certain pressure-volume relationship. After the gastric banding system is flushed with saline to remove any air trapped within the system (e.g., in the gastric band, the tubing, and the port), the pressure-volume relationship generally takes the form illustrated by the “Standard” curve in FIG. 7. The dashed “Compliant” curve illustrates an example embodiment of the pressure-volume relationship for a gastric banding system with one or more compliant components. As illustrated, the self-adjusting gastric banding system may include a greater volume of saline than a standard gastric banding system for a given level of pressure.


The graph in FIG. 8 illustrates, according to various embodiments, pressure characteristics of a “Standard” gastric banding system and a “Self-Adjusting” gastric banding system during use of the systems in a patient. Initially, the two systems are set to the same operating pressure, for example, for a desired level of constriction of the patient's stomach. As a large bolus of food or some other obstruction encounters the gastric band, the pressure in each system increases. As illustrated, the standard system has a larger pressure increase during the period of obstruction than the self-adjusting gastric banding system experiences. This smaller increase in pressure, according to various embodiments, is due to the addition of the reservoir space in the compliant component(s). As pressure in the gastric banding system increases, fluid is transferred into the reservoir space. Once the obstruction passes, the fluid is automatically returned from the reservoir space back into the gastric band.


The various compliant components disclosed herein may have any shape or configuration that facilitates removing an amount of fluid from the inflatable portion of the gastric band in response to an increased pressure in the inflatable portion. For example, the compliant components may be selected from a compressible reservoir, an elastic polymer, a balloon, a rubber container, a silicone container, a collapsible container, a bellows, and combinations thereof that are configured to contain the fluid.


Examples of self adjusting gastric banding systems now having been described, attention will be turned to gastric banding systems with a satiety booster. Occasionally, the patient may desire a little extra help from the gastric band system to avoid overeating. This extra appetite suppression may be achieved by the patient intentionally pressing on an implanted bladder which provides a satiety boost by transfer fluid within the implanted bladder to an inflatable portion of the gastric band, thereby tightening the gastric band and causing the patient to feel full.


In one embodiment, FIG. 9 illustrates a gastric band system 900 which may include a gastric band 905 in fluid communication with a bladder 917 and a port 935. The gastric band system 900 may be implanted between the skin 955 of the patient and the rectus muscle fascia 965. When a patient desires to temporarily suppress appetite, the patient may press on the patient's skin near the location of the bladder 917 as designated by arrow 980. As a patient presses at the location of the arrow 980, pressure may be exerted on the bladder 917, causing fluid from the bladder 917 to be transferred to the gastric band 905, thereby tightening the gastric band 905.


In one embodiment, the gastric band 905 and the port 935 may be implanted as usual with the bladder 917. However, an additional step may be added to the implantation procedure so that a surgeon may tunnel an extra pouch between the skin 955 and the rectus muscle fascia 965. The extra pouch may be positioned under the subcutaneous fat or on top of the subcutaneous fat and the bladder 917 may be positioned within the tunneled pouch. Following surgery, the gastric band 905 may be adjusted as usual by inserting a needle into the access port 935 and adding fluid as necessary. Once the proper adjustment has been made, the patient may feel or experience significantly increased satiety. If the patient feels hungry during a period which their physician has deemed inappropriate (e.g., between normal size meals), the patient may want to temporarily suppress their appetite by pressing on the skin near the arrow 980, as discussed above.



FIG. 10 illustrates one embodiment of a gastric band system 1000. As shown, the gastric band system 1000 may include a gastric band 1005 comprising an inflatable portion 1010 in a compliant ring 1007. The gastric band 1005 may be in fluid communication with the bladder 1017 which in turn may be in fluid communication with an access port 1035. As shown, the bladder 1017 may be of an ellipsoidal shape and may be located between the gastric band 1005 and the access port 1035. However, other placements of the bladder 1017 may be possible.



FIG. 11 illustrates an example of one embodiment where a bladder 1117 is attached on the other side of the access port 1135. As shown, the gastric band system 1100 may include a gastric band 1105 with an inflatable portion 1110 and a ring 1107. The gastric band 1105 may be connected to a tubing 1103 which may be connected to the access port 1135. As shown, when the patient presses on his or her skin at a location near the bladder 1117, fluid within the bladder 1117 may travel through the access port 1135 and the tubing 1103 and into the inflatable portion 1110 of the gastric band 1105, thereby increasing the amount of fluid within the gastric band 1105 and causing the patient to feel satiety.


In one embodiment as shown in FIG. 12, the bladder 1217 may be connected to the gastric banding system 1200 through a “T” connector 1219 such that the bladder 1217 is not in-line with the port 1235 nor the gastric band 1205. In this manner, the “T” connector 1219 may be a part of the tubing 1203 and may allow the bladder 1217 to be in fluid communication with other portions of the gastric banding system 1200 such as a tube component 1214 and an end compliant portion 1216, among other components.


Other methods of fluidly connecting a bladder (e.g., bladder 1217) to a gastric band (e.g., a gastric band 1205) may be possible. For example, a “Y” connector (not shown) or any other type of connector may be used.


Although bladders 1017, 1117, and 1217 in FIGS. 10, 11 and 12 respectively have been shown to be ellipsoidal, other shapes may be possible. For example, FIG. 13 illustrates a flat, circular bladder 1317 while FIG. 14 illustrates a rectangular bladder 1417. The bladders 1317 and 1417 may be implemented anywhere, for example, as bladder 1017 between the gastric band 1005 and the port 1035, or as bladder 1117 coupled to the port 1135. In addition, other shapes may be possible such as a spherical bladder, a prolate spheroid, an oblate spheroid or other suitable shapes (not shown).


The previous bladder shapes, for example, bladders 1017, 1117, 1317 and 1417 may be useful within a limited range of pressures. However, as the pressure within the fluid increases, these bladders 1017, 1117, 1317 and 1417 may bulge and take on a more spherical shape. The bulging characteristics may be reduced or limited by choosing particular combinations of materials and shapes.


Examples of non-bulging bladder shapes are illustrated in FIGS. 15, 16 and 17.


As shown in FIG. 15, bladder 1517 may include a series of connected cylinders having similar shapes and similar sizes. While shown here to be four cylinders, any number of cylinders in series may be possible. The series of connected cylinders of the bladder 1517 may be in fluid communication with each other (e.g., a gap may exist proximal to the point of attachment thereby allowing fluid to be freely transferred between the different cylinders of the bladder 1517). In one embodiment, when a flexible non-stretching material such as polytetrafluoroethylene (PTFE) is formed into a series of connected cylinders, the bladder 1517 may be inflated to its maximum volume and shape. As more fluid is injected into the bladder 1517, the pressure in the system dramatically increases but the shape of the bladder 1517 does not stretch and expand.



FIG. 16 illustrates a bladder 1617 comprising a series of cylinders of various sizes. Again, while shown here to be five cylinders, any number of cylinders in the series may be possible. As shown, the diameter of the middle cylinder of the bladder 1617 may be larger, while the diameter of the outer cylinders may be smaller. Similar to the bladder 1517 of FIG. 15, when a flexible non-stretching material such as PTFE is formed into a series of connected cylinders, the bladder 1617 may be inflated to its maximum volume and shape. As more fluid is injected into the bladder 1617, the pressure in the system dramatically increases but the shape of the bladder 1617 does not stretch and expand.



FIG. 17 illustrates a coil-like bladder 1717. The bladder 1717 may include internal structures that allow the bladder 1717 to inflate (i.e., allowing the diameter of the coils of the bladder 1717 to increase) but without substantially altering the shape of the bladder 1717 (i.e., preventing the bladder 1717 from “uncoiling”). As such, the patient may press on any portion of the bladder 1717 to obtain a boost in satiety.


While different shapes may be possible to construct the bladder, bladder devices are not designed to encourage needle insertion. For example, bladders 1017, 1117, 1317, 1417, 1517, 1617, and 1717 may be constructed out of puncture-resistant fabrics or hard shells to protect the bladders 1017, 1117, 1317, 1417, 1517, 1617, and 1717 from needle punctures. Additionally, the bladders 1017, 1117, 1317, 1417, 1517, 1617, and 1717 may be made resistant to needle punctures by being positioned away from an injection port (e.g., injections ports 1035, 1135).


In one embodiment, the bladders 1017, 1117, 1317, 1417, 1517, 1617, and 1717 may be constructed out of flexible materials such as rubber, silicone, latex and the like and/or thin plastics such as polyethylene (PE), polyethylene terephthalate (PET), polycarbonate (PC), polypropylene (PP), polyamides (PA), PTFE, polyvinyl chloride (PVC), polysulfone (PSU), polyphenylsulfone (PPSU), polyetheretherketone (PEEK), among other fabrics or materials.


While different shapes of bladders have been discussed, the walls within each of the bladders (e.g., the bladders 1017, 1117, 1317, 1417, 1517, 1617, and 1717) may also vary. For example, as shown in FIG. 18, the bladder 1817 may include a tapered wall 1821 shown as the top wall and a uniform wall 1823 shown as a bottom wall. The bladder 1817 of FIG. 18 may be constructed with a tapered wall thinnest at the center of the bladder 1817 where most of the fluid is stored. When the center of the bladder 1817 is pressed, the fluid may be released in an efficient manner instead of being dispersed to the edges of the bladder 1817. However, in certain embodiments, bladders with uniform wall thicknesses throughout may also be possible.


The bladders 1017, 1117, 1317, 1417, 1517, 1617, 1717, and 1817 described herein may be used in conjunction with each other and with other bladders of varying compliance. For example, referring back to FIG. 12, the bladder 1217 may be a non-compliant component and may be used to achieve fluid flow when the patient presses on the bladder 1217. The bladder 1216 may be a compliant component and may be used as an intentional fluid flow creator and as a pressure moderating device. These two bladders 1217 and 1216, among other bladders, may also be used simultaneously such that one non-compliant bladder 1217 may allow for fluid transfer while the other compliant bladder 1216 may act as a pressure monitoring device.


In one or more embodiments, bladders 1017, 1117, 1317, 1417, 1517, 1617, 1717, and 1817 may allow for fluid transfer via one or more mechanisms. Fluid transfer may be intentionally induced when the patient consciously presses on the bladder (e.g., bladders 1017, 1117, 1317, 1417, 1517, 1617, 1717, and 1817) by hand. Fluid transfer may also be unintentionally induced when the patient undergoes daily movement (e.g., stretching, walking, breathing, talking) as these actions may cause pressures on the bladders (e.g., the bladders 1017, 1117, 1317, 1417, 1517, 1617, 1717, and 1817) as well.


In one embodiment, when a patient presses on the bladder 1217 to cause fluid to flow towards the gastric band 1205, the gastric banding system 1200 may be configured to permit the fluid to flow back to the bladder 1217 at a substantially unimpeded rate.


In another embodiment, a flow rate restriction device may be implemented into the bladder 1217 to restrict or control the fluid flow between the bladder 1217 and the gastric band 1205.



FIG. 19 illustrates one embodiment of a flow rate restriction device 1947 within a bladder 1917. FIG. 19A illustrates a close up view of the restriction device 1947. As shown, the flow rate restriction device 1947 may include a flow restrictor 1927 and a duckbill valve 1937 located proximately at an area where a tubing is joined to the bladder 1917. When the patient presses on the bladder 1917, fluid may flow out of the duckbill valve 1937 at one rate and when fluid flows from the gastric band (not shown) back into the bladder 1917, the flow restrictor 1927 may control the flow of the fluid at a second rate.


In one embodiment the rate that fluid leaves the bladder 1917 through the duckbill valve 1937 may be higher than the rate that fluid flows through the flow restrictor 1927 back into the bladder 1917. Conversely, the flow rate of fluid entering the bladder 1917 through the duckbill valve 1937 may be higher than the flow rate of fluid leaving the bladder 1917. Alternatively, the flow rates may be equal.


While a duckbill valve 1937 and a flow restrictor 1927 have been illustrated in FIG. 19, other forms of restriction may be possible.


Unless otherwise indicated, all numbers expressing quantities of ingredients, volumes of fluids, and so forth as used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.


The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.


Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.


Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.


Furthermore, certain references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.


Specific embodiments disclosed herein may be further limited in the claims using consisting of and/or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.


In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims
  • 1. A self-adjusting gastric band for the treatment of obesity that adjusts to provide a satiety boost to a patient, the self-adjusting gastric band comprising: an inflatable portion disposable about an esophageal-gastric junction of the patient;an access port fluidly coupled to the inflatable portion via tubing to fill and drain the inflatable portion;a satiety boosting bladder fluidly coupled to the inflatable portion and the access port, wherein the satiety boosting bladder transfers fluid to the inflatable portion in response to an inwardly directed force effectable by the patient and exerted on the satiety boosting bladder; anda fluid flow rate controlling device, including: a one-way valve that controls fluid flow from the satiety boosting bladder at a first flow rate, anda flow restrictor that controls fluid flow into the satiety boosting bladder at a second flow rate different from the first flow rate, wherein the first and second flow rates are non-zero flow rates.
  • 2. The gastric band of claim 1 further comprising a compliant portion coupled to at least one of the inflatable portion, the access port, the tubing or the satiety boosting bladder, the compliant portion configured to automatically relax the constriction formed by the gastric band and allow a large bolus to pass through the constriction.
  • 3. The gastric band of claim 2 further comprising a ring coupled to the inflatable portion for providing structure and support to the inflatable portion, wherein the ring facilitates disposing the inflatable portion about the esophageal-gastric junction.
  • 4. The gastric band of claim 1 wherein the satiety boosting bladder is configured to transfer fluid to the inflatable portion in response to the patient pressing on the area of skin closest to the satiety boosting bladder.
  • 5. The gastric band of claim 1 wherein the satiety boosting bladder is configured to transfer fluid to the inflatable portion in response to the patient breathing, talking, or moving.
  • 6. The gastric band of claim 1 wherein the satiety boosting bladder is ellipsoidal, circular, or rectangularly shaped.
  • 7. The gastric band of claim 1 wherein the satiety boosting bladder is a series of uniformly sized cylindrical bladders, a series of non-uniformly sized cylindrical bladders, or a coiled bladder.
  • 8. The gastric band of claim 1 wherein the satiety boosting bladder is located between a skin layer and a rectus muscle fascia layer within a body of the patient.
  • 9. The gastric band of claim 1 wherein the satiety boosting bladder comprises a wall of varying thickness.
  • 10. The gastric band of claim 9 wherein the wall comprises a tapered portion near the center of the satiety boosting bladder.
  • 11. The gastric band of claim 1 wherein the satiety boosting bladder is fluidly coupled to the inflatable portion and the access port via a “T-connector”.
  • 12. The gastric band of claim 1 wherein the satiety boosting bladder is fluidly coupled to the inflatable portion and the access port via a “Y-connector”.
  • 13. The gastric band of claim 1 wherein the satiety boosting bladder is further configured to receive fluid from the inflatable portion.
  • 14. The gastric band of claim 1, wherein the fluid flow rate controlling device is within the satiety boosting bladder.
  • 15. A self-adjusting gastric band for the treatment of obesity that adjusts to provide a satiety boost to a patient, the self-adjusting gastric band comprising: an inflatable portion disposable about an esophageal-gastric junction of the patient;an access port fluidly coupled to the inflatable portion via tubing to fill and drain the inflatable portion;a satiety boosting bladder fluidly coupled to the inflatable portion and the access port; anda fluid flow rate controlling device within the satiety boosting bladder, including a one-way valve that controls fluid flow from the satiety boosting bladder at a first flow rate, anda flow restrictor that controls fluid flow into the satiety boosting bladder at a second flow rate different from the first flow rate, wherein the first and second flow rates are non-zero flow rates.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/049,453, filed Mar. 16, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12/770,617, filed on Apr. 29, 2010. The entire contents of which are hereby incorporated by reference herein.

US Referenced Citations (533)
Number Name Date Kind
1174814 Brennan Mar 1916 A
1830947 Klingel Nov 1931 A
1999683 Borresen Apr 1935 A
2163048 McKee Jun 1939 A
2339138 Black Jan 1944 A
2405667 Andrew Aug 1946 A
2438231 Schultz Mar 1948 A
2635907 Heimbuch Apr 1953 A
2714469 Carlson Aug 1955 A
2936980 Rapata May 1960 A
3059645 Hasbrouck Oct 1962 A
3189961 Heller Jun 1965 A
3667081 Burger Jun 1972 A
3840018 Heifetz Oct 1974 A
3955834 Ahlrot May 1976 A
4053176 Hilbush Oct 1977 A
4118805 Reimels Oct 1978 A
4133315 Berman Jan 1979 A
4157713 Clarey Jun 1979 A
4176412 Peterson Dec 1979 A
4236521 Lauterjung Dec 1980 A
4271827 Angelchik Jun 1981 A
4299012 Oetiker Nov 1981 A
4340083 Cummins Jul 1982 A
4399809 Baro Aug 1983 A
4408597 Tenney Oct 1983 A
4417567 Trick Nov 1983 A
4424208 Wallace Jan 1984 A
4442153 Meltsch Apr 1984 A
4450375 Siegal May 1984 A
4485805 Foster Dec 1984 A
4492004 Oetiker Jan 1985 A
4551862 Haber Nov 1985 A
4558699 Bashour Dec 1985 A
4559699 Owen Dec 1985 A
4582640 Smestad Apr 1986 A
4582865 Balazs Apr 1986 A
4592339 Kuzmak Jun 1986 A
4592355 Antebi Jun 1986 A
4601713 Fuqua Jul 1986 A
4667672 Romanowski May 1987 A
4671351 Rappe Jun 1987 A
4693695 Cheng Sep 1987 A
4694827 Weiner Sep 1987 A
4696288 Kuzmak Sep 1987 A
4708140 Baron Nov 1987 A
4716154 Maelson Dec 1987 A
4753086 Schmidt Jun 1988 A
4760837 Petit Aug 1988 A
4803075 Wallace Feb 1989 A
4881939 Newman Nov 1989 A
4883467 Franetzki Nov 1989 A
4886787 De Dec 1989 A
4896787 Delamour Jan 1990 A
4915690 Cone Apr 1990 A
4925446 Garay May 1990 A
4944487 Holtermann Jul 1990 A
4944659 Labbe Jul 1990 A
4958791 Nakamura Sep 1990 A
4969899 Cox Nov 1990 A
4994019 Fernandez Feb 1991 A
5045060 Melsky Sep 1991 A
5074868 Kuzmak Dec 1991 A
5084061 Gau Jan 1992 A
5091171 Yu Feb 1992 A
5116652 Alzner May 1992 A
5120313 Elftman Jun 1992 A
5143724 Leshchiner Sep 1992 A
5152770 Bengmark Oct 1992 A
5160338 Vincent Nov 1992 A
5188609 Bayless Feb 1993 A
5224494 Enhorning Jul 1993 A
5226429 Kuzmak Jul 1993 A
5246456 Wilkinson Sep 1993 A
5246698 Leshchiner Sep 1993 A
5259399 Brown Nov 1993 A
5326349 Baraff Jul 1994 A
5343894 Frisch Sep 1994 A
5356883 Kuo et al. Oct 1994 A
5360445 Goldowsky Nov 1994 A
5391156 Hildwein Feb 1995 A
5399351 Leshchiner Mar 1995 A
5449363 Brust Sep 1995 A
5449368 Kuzmak Sep 1995 A
5458568 Racchini Oct 1995 A
5509888 Miller Apr 1996 A
5531716 Luzio Jul 1996 A
5535752 Halperin Jul 1996 A
5554113 Novak Sep 1996 A
5562714 Grevious Oct 1996 A
5601604 Vincent Feb 1997 A
5607418 Arzbaecher Mar 1997 A
5633001 Ågerup May 1997 A
5653718 Yoon Aug 1997 A
5658298 Vincent Aug 1997 A
5676162 Larson Oct 1997 A
5695504 Gifford Dec 1997 A
5704893 Timm Jan 1998 A
5713911 Racenet Feb 1998 A
5733257 Sternby Mar 1998 A
5748200 Funahashi May 1998 A
5766232 Grevious Jun 1998 A
5769877 Barreras Jun 1998 A
5785295 Tsai Jul 1998 A
5817113 Gifford Oct 1998 A
5827529 Ono Oct 1998 A
5833698 Hinchliffe Nov 1998 A
5861014 Familoni Jan 1999 A
RE36176 Kuzmak Mar 1999 E
5886042 Yu Mar 1999 A
5904697 Gifford May 1999 A
5910149 Kuzmak Jun 1999 A
5928195 Malamud Jul 1999 A
5938669 Klaiber Aug 1999 A
5944696 Bayless Aug 1999 A
5944751 Laub Aug 1999 A
5993473 Chan Nov 1999 A
6013679 Kuo Jan 2000 A
6024340 Lazarus Feb 2000 A
6024704 Meador Feb 2000 A
6048309 Flom Apr 2000 A
6067991 Forsell May 2000 A
6074341 Anderson Jun 2000 A
6074378 Mouri Jun 2000 A
6083249 Familoni Jul 2000 A
6090131 Daley Jul 2000 A
6102678 Peclat Aug 2000 A
6102922 Jakobsson Aug 2000 A
6171321 Gifford Jan 2001 B1
6193734 Bolduc Feb 2001 B1
6203523 Haller Mar 2001 B1
6210345 Van Brunt Apr 2001 B1
6210347 Forsell Apr 2001 B1
6221024 Miesel Apr 2001 B1
6224857 Romeo May 2001 B1
6306088 Krausman Oct 2001 B1
6327503 Familoni Dec 2001 B1
6371965 Gifford Apr 2002 B2
6372494 Naughton Apr 2002 B1
6383218 Sourdile May 2002 B1
6383219 Telandro May 2002 B1
6387105 Gifford May 2002 B1
6417750 Sohn Jul 2002 B1
6418934 Chin Jul 2002 B1
6419696 Ortiz Jul 2002 B1
6432040 Meah Aug 2002 B1
6439539 Powell Aug 2002 B1
6443957 Addis Sep 2002 B1
6443965 Gifford Sep 2002 B1
6450173 Forsell Sep 2002 B1
6450946 Forsell Sep 2002 B1
6451034 Gifford Sep 2002 B1
6453907 Forsell Sep 2002 B1
6454699 Forsell Sep 2002 B1
6454700 Forsell Sep 2002 B1
6454701 Forsell Sep 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6457801 Fish Oct 2002 B1
6460543 Forsell Oct 2002 B1
6461293 Forsell Oct 2002 B1
6463935 Forsell Oct 2002 B1
6464628 Forsell Oct 2002 B1
6470892 Forsell Oct 2002 B1
6474584 Ekich Nov 2002 B2
6475136 Forsell Nov 2002 B1
6485496 Suyker Nov 2002 B1
6491704 Gifford Dec 2002 B2
6491705 Gifford Dec 2002 B2
6511490 Robert Jan 2003 B2
6517556 Monassevitch Feb 2003 B1
6527701 Sayet Mar 2003 B1
6547801 Dargent Apr 2003 B1
6565582 Gifford May 2003 B2
6579301 Bales Jun 2003 B1
6601604 Cooper Aug 2003 B1
6615084 Cigaina Sep 2003 B1
6627620 Nielsen Sep 2003 B1
6630486 Royer Oct 2003 B1
6632239 Snyder Oct 2003 B2
6646628 Shirochi Nov 2003 B2
6676674 Dudai Jan 2004 B1
6685668 Cho Feb 2004 B1
6685963 Taupin Feb 2004 B1
6691047 Fredericks Feb 2004 B1
6715731 Post Apr 2004 B1
6729600 Mattes May 2004 B2
6754527 Stroebel Jun 2004 B2
6767924 Yu Jul 2004 B2
6811136 Eberhardt Nov 2004 B2
6820651 Seuret Nov 2004 B2
6834201 Gillies Dec 2004 B2
6871090 He Mar 2005 B1
6889086 Mass May 2005 B2
6916326 Benchetrit Jul 2005 B2
6921819 Piron Jul 2005 B2
6924273 Pierce Aug 2005 B2
6940467 Fischer Sep 2005 B2
6966875 Longobardi Nov 2005 B1
7017583 Forsell Mar 2006 B2
7021147 Subramanian Apr 2006 B1
7037344 Kagan May 2006 B2
7040349 Moler May 2006 B2
7054690 Imran May 2006 B2
7058434 Wang Jun 2006 B2
7060080 Bachmann Jun 2006 B2
7066486 Lee Jun 2006 B2
7118526 Egle Oct 2006 B2
7119062 Alvis Oct 2006 B1
7128750 Stergiopulos Oct 2006 B1
7144400 Byrum Dec 2006 B2
7172607 Hoefle Feb 2007 B2
7177693 Starkebaum Feb 2007 B2
7191007 Desai Mar 2007 B2
7204821 Clare Apr 2007 B1
7223239 Schulze May 2007 B2
7238191 Bachmann Jul 2007 B2
7240607 Fish Jul 2007 B2
7255675 Gertner Aug 2007 B2
7263405 Boveja Aug 2007 B2
7282023 Frering Oct 2007 B2
7288064 Boustani Oct 2007 B2
7297103 Jarsaillon Nov 2007 B2
7299082 Feldman Nov 2007 B2
7310557 Maschino Dec 2007 B2
7311716 Byrum Dec 2007 B2
7311717 Egle Dec 2007 B2
7314443 Jordan Jan 2008 B2
7314636 Caseres Jan 2008 B2
7338433 Coe Mar 2008 B2
7340306 Barrett Mar 2008 B2
7351198 Byrum Apr 2008 B2
7351240 Hassler Apr 2008 B2
7364542 Jambor Apr 2008 B2
7367340 Nelson May 2008 B2
7367937 Jambor May 2008 B2
7374565 Hassler May 2008 B2
7390294 Hassler Jun 2008 B2
7396353 Lorenzen Jul 2008 B2
7416528 Crawford Aug 2008 B2
7457668 Cancel Nov 2008 B2
7481763 Hassler Jan 2009 B2
7500944 Byrum Mar 2009 B2
7502649 Ben-Haim Mar 2009 B2
7530943 Lechner May 2009 B2
7594885 Byrum Sep 2009 B2
7599743 Hassler Oct 2009 B2
7599744 Giordano Oct 2009 B2
7601162 Hassler Oct 2009 B2
7615001 Jambor Nov 2009 B2
7618365 Jambor Nov 2009 B2
7658196 Ferreri Feb 2010 B2
7670279 Gertner Mar 2010 B2
7699770 Hassler Apr 2010 B2
7712470 Gertner May 2010 B2
7727141 Hassler Jun 2010 B2
7741476 Lebreton Jun 2010 B2
7758493 Gingras Jul 2010 B2
7763039 Ortiz Jul 2010 B2
7766815 Ortiz Aug 2010 B2
7771439 Griffiths Aug 2010 B2
7775215 Hassler Aug 2010 B2
7775966 Dlugos Aug 2010 B2
7775967 Gertner Aug 2010 B2
7794386 Brooks Sep 2010 B2
7811298 Birk Oct 2010 B2
7824422 Benchetrit Nov 2010 B2
7828813 Mouton Nov 2010 B2
7832407 Gertner Nov 2010 B2
7841978 Gertner Nov 2010 B2
7844342 Dlugos Nov 2010 B2
7862502 Pool Jan 2011 B2
7879068 Dlugos Feb 2011 B2
7951067 Byrum May 2011 B2
20010011543 Forsell Aug 2001 A1
20020072780 Foley Jun 2002 A1
20020091395 Gabbay Jul 2002 A1
20020095181 Beyar Jul 2002 A1
20020098097 Singh Jul 2002 A1
20020139208 Yatskov Oct 2002 A1
20020183765 Adams Dec 2002 A1
20020193679 Malave Dec 2002 A1
20020198548 Robert Dec 2002 A1
20030014003 Gertner Jan 2003 A1
20030019498 Forsell Jan 2003 A1
20030045775 Forsell Mar 2003 A1
20030045902 Weadock Mar 2003 A1
20030060873 Gertner Mar 2003 A1
20030066536 Forsell Apr 2003 A1
20030073880 Polsky Apr 2003 A1
20030093157 Casares May 2003 A1
20030100910 Gifford May 2003 A1
20030120288 Benchetrit Jun 2003 A1
20030148995 Piron Aug 2003 A1
20030158564 Benchetrit Aug 2003 A1
20030158569 Wazne Aug 2003 A1
20030181890 Schulze Sep 2003 A1
20030181917 Gertner Sep 2003 A1
20030191433 Prentiss Oct 2003 A1
20030208212 Cigaina Nov 2003 A1
20040000843 East Jan 2004 A1
20040044332 Stergiopulos Mar 2004 A1
20040049209 Benchetrit Mar 2004 A1
20040059393 Policker Mar 2004 A1
20040064110 Forsell Apr 2004 A1
20040068847 Belisle Apr 2004 A1
20040106899 McMichael Jun 2004 A1
20040133219 Forsell Jul 2004 A1
20040147816 Policker Jul 2004 A1
20040148034 Kagan Jul 2004 A1
20040153106 Dudai Aug 2004 A1
20040162595 Foley Aug 2004 A1
20040215159 Forsell Oct 2004 A1
20040230137 Mouton Nov 2004 A1
20040254536 Conlon Dec 2004 A1
20040254537 Conlon Dec 2004 A1
20040260319 Egle Dec 2004 A1
20040267288 Byrum Dec 2004 A1
20040267291 Byrum Dec 2004 A1
20040267292 Byrum Dec 2004 A1
20040267293 Byrum Dec 2004 A1
20040267377 Egle Dec 2004 A1
20050002984 Byrum Jan 2005 A1
20050038484 Knudson Feb 2005 A1
20050038498 Dubrow Feb 2005 A1
20050055039 Burnett Mar 2005 A1
20050070934 Tanaka Mar 2005 A1
20050070937 Jambor et al. Mar 2005 A1
20050082793 Lee Apr 2005 A1
20050100779 Gertner May 2005 A1
20050104457 Jordan May 2005 A1
20050119672 Benchetrit Jun 2005 A1
20050119674 Gingras Jun 2005 A1
20050131383 Chen Jun 2005 A1
20050131485 Knudson Jun 2005 A1
20050136122 Sadozai Jun 2005 A1
20050142152 Leshchiner Jun 2005 A1
20050143765 Bachmann Jun 2005 A1
20050143766 Bachmann Jun 2005 A1
20050154274 Jarsaillon Jul 2005 A1
20050171568 Duffy Aug 2005 A1
20050183730 Byrum Aug 2005 A1
20050192531 Birk Sep 2005 A1
20050192601 Demarais Sep 2005 A1
20050192629 Saadat Sep 2005 A1
20050216042 Gertner Sep 2005 A1
20050226936 Agerup Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050240155 Conlon Oct 2005 A1
20050240156 Conlon Oct 2005 A1
20050240279 Kagan Oct 2005 A1
20050244288 O'Neill Nov 2005 A1
20050250979 Coe Nov 2005 A1
20050251181 Bachmann Nov 2005 A1
20050251182 Bachmann Nov 2005 A1
20050267406 Hassler Dec 2005 A1
20050267500 Hassler Dec 2005 A1
20050267533 Gertner Dec 2005 A1
20050271729 Wang Dec 2005 A1
20050277899 Conlon Dec 2005 A1
20050283041 Egle Dec 2005 A1
20050288739 Hassler Dec 2005 A1
20050288740 Hassler Dec 2005 A1
20060015138 Gertner Jan 2006 A1
20060020298 Camilleri Jan 2006 A1
20060041183 Massen Feb 2006 A1
20060074439 Garner Apr 2006 A1
20060074473 Gertner Apr 2006 A1
20060089571 Gertner Apr 2006 A1
20060122147 Wohlrab Jun 2006 A1
20060127246 Forsell Jun 2006 A1
20060142700 Sobelman Jun 2006 A1
20060142790 Gertner Jun 2006 A1
20060161139 Levine Jul 2006 A1
20060161186 Hassler Jul 2006 A1
20060167531 Gertner Jul 2006 A1
20060173238 Starkebaum Aug 2006 A1
20060173424 Conlon Aug 2006 A1
20060183967 Lechner Aug 2006 A1
20060189887 Hassler Aug 2006 A1
20060189888 Hassler Aug 2006 A1
20060189889 Gertner Aug 2006 A1
20060194758 Lebreton Aug 2006 A1
20060195139 Gertner Aug 2006 A1
20060197412 Rasmussen Sep 2006 A1
20060199997 Hassler Sep 2006 A1
20060211912 Dlugos Sep 2006 A1
20060211913 Dlugos Sep 2006 A1
20060211914 Hassler Sep 2006 A1
20060212051 Snyder Sep 2006 A1
20060212053 Gertner Sep 2006 A1
20060229696 Boustani Oct 2006 A1
20060235448 Roslin Oct 2006 A1
20060246137 Hermitte Nov 2006 A1
20060247721 Maschino Nov 2006 A1
20060247722 Maschino Nov 2006 A1
20060252982 Hassler Nov 2006 A1
20060252983 Lembo Nov 2006 A1
20060257488 Hubbard Nov 2006 A1
20060264699 Gertner Nov 2006 A1
20060276812 Hill Dec 2006 A1
20060293627 Byrum Dec 2006 A1
20070015954 Dlugos Jan 2007 A1
20070015955 Tsonton Jan 2007 A1
20070015956 Crawford Jan 2007 A1
20070016231 Jambor Jan 2007 A1
20070016262 Gross Jan 2007 A1
20070027356 Ortiz Feb 2007 A1
20070027358 Gertner Feb 2007 A1
20070044655 Fish Mar 2007 A1
20070077292 Pinsky Apr 2007 A1
20070078476 Hull Apr 2007 A1
20070125826 Shelton Jun 2007 A1
20070156013 Birk Jul 2007 A1
20070167672 Dlugos Jul 2007 A1
20070167982 Gertner Jul 2007 A1
20070173685 Jambor Jul 2007 A1
20070173888 Gertner Jul 2007 A1
20070179335 Gertner Aug 2007 A1
20070185373 Tsonton Aug 2007 A1
20070185462 Byrum Aug 2007 A1
20070213836 Paganon Sep 2007 A1
20070218083 Brooks Sep 2007 A1
20070232848 Forsell Oct 2007 A1
20070232849 Gertner Oct 2007 A1
20070233170 Gertner Oct 2007 A1
20070235083 Dlugos Oct 2007 A1
20070243227 Gertner Oct 2007 A1
20070250085 Bachmann Oct 2007 A1
20070250086 Wiley Oct 2007 A1
20070255335 Herbert Nov 2007 A1
20070255336 Herbert Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070265645 Birk Nov 2007 A1
20070265646 McCoy Nov 2007 A1
20070293716 Baker Dec 2007 A1
20070298005 Thibault Dec 2007 A1
20080009680 Hassler Jan 2008 A1
20080015406 Dlugos Jan 2008 A1
20080015501 Gertner Jan 2008 A1
20080027269 Gertner Jan 2008 A1
20080027469 Bachmann Jan 2008 A1
20080071306 Gertner Mar 2008 A1
20080097496 Chang Apr 2008 A1
20080108862 Jordan May 2008 A1
20080147002 Gertner Jun 2008 A1
20080161717 Gertner Jul 2008 A1
20080161875 Stone Jul 2008 A1
20080167647 Gertner Jul 2008 A1
20080167648 Gertner Jul 2008 A1
20080172072 Pool Jul 2008 A1
20080188766 Gertner Aug 2008 A1
20080195092 Kim Aug 2008 A1
20080208240 Paz Aug 2008 A1
20080221598 Dlugos Sep 2008 A1
20080243071 Quijano Oct 2008 A1
20080249806 Dlugos Oct 2008 A1
20080250340 Dlugos Oct 2008 A1
20080250341 Dlugos Oct 2008 A1
20080255403 Voegele Oct 2008 A1
20080255414 Voegele Oct 2008 A1
20080255425 Voegele Oct 2008 A1
20080255459 Voegele Oct 2008 A1
20080255537 Voegele Oct 2008 A1
20080275294 Gertner Nov 2008 A1
20080275295 Gertner Nov 2008 A1
20080275484 Gertner Nov 2008 A1
20080281347 Gertner Nov 2008 A1
20080287969 Tsonton Nov 2008 A1
20080287974 Widenhouse Nov 2008 A1
20080287976 Weaner Nov 2008 A1
20080300618 Gertner Dec 2008 A1
20080319435 Rioux Dec 2008 A1
20090054914 Lechner Feb 2009 A1
20090062825 Pool Mar 2009 A1
20090062826 Steffen Mar 2009 A1
20090082793 Birk Mar 2009 A1
20090118572 Lechner May 2009 A1
20090149874 Ortiz Jun 2009 A1
20090157106 Marcotte Jun 2009 A1
20090157107 Kierath Jun 2009 A1
20090157113 Marcotte Jun 2009 A1
20090171375 Coe Jul 2009 A1
20090171378 Coe Jul 2009 A1
20090171379 Coe Jul 2009 A1
20090187202 Ortiz Jul 2009 A1
20090192404 Ortiz Jul 2009 A1
20090192415 Ortiz Jul 2009 A1
20090192533 Dlugos Jul 2009 A1
20090192534 Ortiz Jul 2009 A1
20090192541 Ortiz Jul 2009 A1
20090198261 Schweikert Aug 2009 A1
20090202387 Dlugos Aug 2009 A1
20090204131 Ortiz Aug 2009 A1
20090204132 Ortiz Aug 2009 A1
20090209995 Byrum Aug 2009 A1
20090216255 Coe et al. Aug 2009 A1
20090216256 Nicholson Aug 2009 A1
20090220176 Fusco Sep 2009 A1
20090222031 Axelsson Sep 2009 A1
20090222065 Dlugos Sep 2009 A1
20090228063 Dlugos Sep 2009 A1
20090228072 Coe Sep 2009 A1
20090240100 Forsell Sep 2009 A1
20090270904 Birk et al. Oct 2009 A1
20090306462 Lechner Dec 2009 A1
20100010291 Birk Jan 2010 A1
20100049224 Vargas Feb 2010 A1
20100087843 Bertolote Apr 2010 A1
20100099945 Birk Apr 2010 A1
20100100079 Berkcan Apr 2010 A1
20100770617 Snow Apr 2010
20100145378 Gertner Jun 2010 A1
20100152532 Marcotte Jun 2010 A1
20100168508 Gertner Jul 2010 A1
20100185049 Birk Jul 2010 A1
20100191265 Lau Jul 2010 A1
20100191271 Lau Jul 2010 A1
20100204647 Gertner Aug 2010 A1
20100204723 Gertner Aug 2010 A1
20100217071 Ricol Aug 2010 A1
20100226988 Lebreton Sep 2010 A1
20100228080 Tavori Sep 2010 A1
20100234682 Gertner Sep 2010 A1
20100249803 Griffiths Sep 2010 A1
20100280310 Raven Nov 2010 A1
20100305397 Birk Dec 2010 A1
20100312046 Lau Dec 2010 A1
20100312147 Gertner Dec 2010 A1
20100324358 Birk Dec 2010 A1
20100324359 Birk Dec 2010 A1
20110071341 Dlugos Mar 2011 A1
20110201874 Birk Aug 2011 A1
Foreign Referenced Citations (106)
Number Date Country
949965 Jun 1974 CA
0230747 Aug 1987 EP
0416250 Mar 1991 EP
0611561 Aug 1994 EP
1036545 Sep 2000 EP
1072282 Jan 2001 EP
1105073 Jun 2001 EP
1491167 Dec 2004 EP
1491168 Dec 2004 EP
1529502 May 2005 EP
1547549 Jun 2005 EP
1574189 Sep 2005 EP
1600183 Nov 2005 EP
1602346 Dec 2005 EP
1704833 Sep 2006 EP
1719480 Nov 2006 EP
1736123 Dec 2006 EP
1736195 Dec 2006 EP
1736202 Dec 2006 EP
1743605 Jan 2007 EP
1829504 Sep 2007 EP
1829505 Sep 2007 EP
1829506 Sep 2007 EP
1967168 Sep 2008 EP
1992315 Nov 2008 EP
2074970 Jul 2009 EP
2074971 Jul 2009 EP
2074972 Jul 2009 EP
2095796 Sep 2009 EP
2095798 Sep 2009 EP
2191796 Jun 2010 EP
2688693 Sep 1993 FR
2769491 Apr 1999 FR
2799118 Apr 2001 FR
1174814 Dec 1969 GB
2090747 Jul 1982 GB
57171676 Oct 1982 JP
2019147 Jan 1990 JP
11244395 Sep 1999 JP
2003526410 Sep 2003 JP
2005131380 May 2005 JP
8600079 Jan 1986 WO
8600912 Feb 1986 WO
8911701 Nov 1989 WO
9000369 Jan 1990 WO
9220349 Nov 1992 WO
9402517 Feb 1994 WO
9633751 Jan 1996 WO
9835639 Aug 1998 WO
9835640 Aug 1998 WO
0000108 Jan 2000 WO
0001428 Jan 2000 WO
0009047 Feb 2000 WO
0009049 Feb 2000 WO
0015158 Mar 2000 WO
0066196 Nov 2000 WO
0110359 Feb 2001 WO
0112078 Feb 2001 WO
0141671 Jun 2001 WO
0147435 Jul 2001 WO
0147575 Jul 2001 WO
0149245 Jul 2001 WO
0152777 Jul 2001 WO
0168007 Sep 2001 WO
0185071 Nov 2001 WO
0205753 Jan 2002 WO
0209792 Feb 2002 WO
0219953 Mar 2002 WO
0226317 Apr 2002 WO
02053093 Jul 2002 WO
02065948 Aug 2002 WO
02096326 Dec 2002 WO
03007782 Jan 2003 WO
03055420 Jul 2003 WO
03057092 Jul 2003 WO
03059215 Jul 2003 WO
03077191 Sep 2003 WO
03101352 Dec 2003 WO
03105732 Dec 2003 WO
2004014245 Feb 2004 WO
2004019671 Mar 2004 WO
2004108025 Dec 2004 WO
2004112563 Dec 2004 WO
2005007232 Jan 2005 WO
2005009305 Feb 2005 WO
2005067994 Jul 2005 WO
2005072195 Aug 2005 WO
2005087147 Sep 2005 WO
2005094447 Oct 2005 WO
2005112888 Dec 2005 WO
2006040647 Apr 2006 WO
2006049725 May 2006 WO
2006083885 Aug 2006 WO
2006108203 Oct 2006 WO
2007067206 Jun 2007 WO
2007081304 Jul 2007 WO
2007106727 Sep 2007 WO
2007114905 Oct 2007 WO
2007145638 Dec 2007 WO
2008058028 May 2008 WO
2008063673 May 2008 WO
2008134755 Nov 2008 WO
2009050709 Apr 2009 WO
2009132127 Oct 2009 WO
2009136126 Nov 2009 WO
2010042493 Apr 2010 WO
Non-Patent Literature Citations (85)
Entry
Acuna-Goycolea et al.; ‘Mechanism of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Acruate Nucleus’; The Journal of Neuroscience; V. 25(32); pp. 7406-7419; Aug. 10, 2005.
Adrian et al.; ‘Mechanism of Pancreatic Polypeptide Release in Man.’ The Lancet; pp. 161-163; Jan. 22, 1977.
Anson; ‘Shape Memory Alloys—Medical Applications,’ Source: Materials World, vol. 7, No. 12, pp. 745-747, Dec. 1999.
Asakawa et al; ‘Antagonism of Ghrelin Receptor Reduces Food Intake and Body Weight Gain in Mice’; Gut.; V.52; pp. 947-952; 2003.
Baggio et al. ‘Biology of Integrins: GLP-1 and GIP’; Gastroenrology; V. 132; pp. 2131-2157; 2007.
Ballantyne; ‘Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release, and Actions’; Obesity Surgery; V.16; pp. 651-658; 2006.
Ballantyne; “Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery”; Obesity Surgery; V.16; pp. 795-803; 2006.
Berne et al; ‘Physiology’; V. 5; pp. 55-57, 210, 428, 540, 554, 579, 584, 591; 2004.
Bio Enterics Lap-Band Adjustable Gastric Banding System, Inamed Health, pub. Aug. 28, 2003, pp. 1-115.
Boulant et al.; ‘Cholecystokinin in Transient Lower Oesophageal Sphincter Relation Due to Gastric Distension in Humans’; Gut; V. 40; pp. 575-581; 1997.
Bradjewin et al; ‘Dose Ranging Study of the Effects of Cholecystokinin in Healthy Volunteers’; J. Psychiatr. Neurosci.; V. 16 (2); pp. 91-95; 1991.
Burdyga et al.; ‘Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach’; The Journal of Neuroscience; V. 28; No. 45; pp. 11583-11592; Nov. 5, 2008.
Chaptini et al.; “Neuroendocrine Regulation of Food Intake”; Current Opinion in Gastroenterology; V. 24; pp. 223-229; 2008.
Chaudhri; ‘Can Gut Hormones Control Appetite and Prevent Obesity?’ Diabetes Care; V. 31; Supp 2; pp. S284-S289; Feb. 2008.
Cohen et al.; ‘Oxyntomodulin Suppresses Appetite and Reduces Food in Humans’; J. Clin. Endocrinol. Metab.; V. 88; pp. 4696-4701; 2003.
Corno et al.; ‘A new implantable device for telemetric control of pulmonary blood flow’; New ideas; received Apr. 24, 2004; received in revised form Jul. 12, 2002; 10 pages.
Corno et al.; ‘FlowWatchTM in clipped and inclipped position’; Interact Cardio Vase Thorac Surg 2002; 1:46-49; Copyright@2002 The European Asociation for Cardio-thoracic Surgery; 1 page.
Cummings et al.; ‘Plasma Ghrelin Levels After Diet-Induced Weight Loss or Gastric Bypass Surgery’; N. Engl J. Med; V. 346, No. 21; pp. 1623-1630; May 23, 2002.
Cummings; ‘Gastrointestinal Regulation of Foot Intake’; The Food Journal of Clinical Investigation; V. 117, N. 1; pp. 13-23; Jan. 2007.
Dakin et al.; ‘Oxyntomodulin Inhibits Food Intake in the Rat’; Endocrinology; V. 142; pp. 4244-4250; 2001.
Dakin et al.; ‘Peripheral Oxyntomodulin Reduces Food Intake and Body Weight gain in Rats’; Endocrinology; V. 145; No. 6; pp. 2687-2695; Jun. 2004.
Davison; ‘Activation of Vagal-Gastric Mechanoreceptors by Cholecystokinin’; Proc. West. Pharmocol. Soc; V. 29; pp. 363-366; 1986.
De Waele et al.; “Endoscopic Volume Adjustment of Intragastric Balloons for Intolerance”; Obesity Surgery; V. 11; pp. 223-224; 2001.
De Waele et al.; “Intragastric Balloons for Preoperative Weight Reduction”; Obesity Surgery; V. 58; pp. 58-60; 2001.
Desai et al.; ‘Molecular Weight of Heparin Using 13C Nuclear Magnetic Resonance Spectroscopy’ Journal of Pharmaceutical Science, V. 84,12; 1995, Abstract only.
Doldi et al.; ‘Intragastric Balloon: Another Option for Treatment of Obesity and Morbid Obesity’; Hepato-Gastroenterology; V. 51, N. 55; pp. 294-307; Jan.-Feb. 2004.
Doldi et al.; ‘Treatment of Morbid Obesity with Intragastric Balloon in Association with Diet’; Obesity Surgery; V. 10, pp. 583-587; 2000.
Ekblad et al.; ‘Distribution of Pancreatic Peptide and Peptide-YY’; Peptides; V. 23; pp. 251-261;2002.
El Khoury et al.; “Variation in Postprandial Ghrelin Status Following Ingestion of High-Carbohydrate, High Fat, and High Protein Meals in Males”; Ann Nutr Metab; V. 50; pp. 260-269; 2006.
Galloro et al; “Preliminary Endoscopic Technical Report of an New Silicone Intragastric Balloon in the Treatment of Morbid Obesity”; Obesity Surgery; V. 9, pp. 68-71; 1999.
GinShiCel MH Hydroxy Propyl Methyl Cellulose, Web Page http://www.ginshicel.cn/MHPC.html, Nov. 12, 2008.
Girard; ‘The Incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: IncretinsIncretinsIncretinsIncretinsIncretins: Concept and physiological functions’; Diabetes and Metabolism; V. 34; pp. 550-559; 2008.
Greenough et al.; ‘Untangling the Effects of Hunger, Anxiety and Nausea on Energy Intake During Intravenous Cholecystokinin Octapeptide (CCK-8) Infusion’ Physiology and Behavior; V. 65 (2); pp. 303-310; 1998.
Grise et al.; “Peptide YY Inhibits Growth of Human Breast Cancer in Vitro and in Vivo”; Journal of Surgical Research; V. 82; pp. 151-155; 1999.
Grundy; “Signaling the State of the Digestive Tract”; Autonomic Neuroscience: Basic and Clinical; V. 125; pp. 76-80; 2006.
Grundy; “Vagal Control of Gastrointestinal Function”; Bailliere's Clinical Gastroenterology; V. 2; No. 1; pp. 23-43; 1988.
Hallden et al. “Evidence for a Role of the Gut Hormone PYY in the Regulation of Intestinal Fatty Acid Binding Protein Transcripts in Differentiated Subpopulations of Intestinal Epithelial Cell Hybrids”; Journal of Biological Chemistry; V. 272 (19); pp. 125916-126000; 1997.
Hameed et al., ‘Gut Hormones and Appetite Control’, Oral Diseases, 2009, 15:18-26.
Hassan et al.; ‘Effects of Adjuvants to Local Anesthetics on Their Duration III Experimental Studies of Hyaluronic Acid’ Abstract Pub Med [Acta Anesthesiol Scand.; 29 (4): 384-8], 1 page; May 1985.
Hodson et al.; ‘Management of Obesity with the New Intragastric Balloon’; Obesity Surgery; V. 11, pp. 327-329,2001.
Holzer; “Gastrointestinal Afferents as Targets of Novel Drugs for the Treatment of Functional Bowel Disorders and Visceral Pain”; European Journal of Pharmacology; V. 429; pp. 177-193; 2001.
Houpt; ‘Gastrointestinal Factors in Hunger and Satiety’; Neurosci. and Behav. Rev.; V. 6; pp. 145-164; 1982.
Jones; “Molecular, pharmacological, and clinical aspects of liraglutide, a oncedaily human GLP-1 analogue”; Molecular and Cellular Endocrinology; V. 297; pp. 137-140; 2009.
Kerem et al.; ‘Exogenous Ghrelin Enhances Endocrine and Exocrine Regeneration in Pancreatectomized Rats’; J. Gastrointest Surg.; V. 13; pp. 775-783, 2009.
Kesty et al., ‘Hormone-based Therapies in the Regulation of Fuel Metabolism and Body Weight’, Expert Opin. Biol. Ther., 2008, 8(11): 1733-1747.
Kissileff et al.; ‘Peptides that Regulate Food Intake: Cholecystokinin and Stomach Distension Combine to Reduce Food Intake in Humans’; Am. J. Physiol. Regul. lntegr. Comp. Physiol.; V. 285; pp. 992-998; 2003.
Kojima et al., ‘A Role for Pancreatic Polypeptide in Feeding and Body Weight Regulation’, Peptides, 2007, 28:459-463.
Kulicke et al. “Visco-Elastic Propeerties of Sodium Hyaluronate Solutions,” American Institute of Physics; pp. 585-587; 2008.
Lap-Band AP System Adjustable Gastric Banding System With OmniformTM Design: Directions for Use (DFU); Allergan, 16 pages; 2009.
Le Roux et al.; ‘Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters’; Ann. Surg; V. 243; No. 1; pp. 108-114; Jan. 2006.
Liu et al.; ‘Adjuvant Hormonal Treatment With Peptide YY or Its Analog Decreases Human Pancreatic Carcinoma Growth’; The American Journal of Surgery; V. 171; pp. 192-196; Jan. 1996.
Mathus-Vliegen et al. ‘Intragastric Balloons for Morbid Obesity: Results, Patient Tolerance and Balloon Life Span’; Br. J. Surg.; V. 77, No. 7, pp. 76-79; Jan. 1990.
Mathus-Vliegen et al. “Treating Morbid and Supermorbid Obesity” International Journal of Gastroenterology; V. 5, No. 1, pp. 9-12; 2000.
Medeiros et al.; ‘Processing and metabolism of Peptide-YY: Pivotal roles of Dipeptidase-IV, Aminopeptidase-P, and Endopeptidase-24.11’; Endocrinology; V. 134, No. 5; pp. 2088-2094;1994.
Naslund et al.; ‘Prandial Subcutaneous Injection of Glucagon-Like Peptide’; Br. J. Nutr.; V. 91; pp. 439-446; 2004.
Potier et al.; “Protein, amino acids, and the control of food intake”; Current Opinion in Clinical Nutrition and Metabolic Care; V. 12; pp. 54-58; 2009.
Qjan et al.; ‘Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117’; International Journal of Pharmaceutics; V. 366; pp. 218-220; 2008.
Rang et al.; ‘Pharmacology’; V. 5; pp. 203, 397, 402, 524; 2004.
Raybould et al.; “Integration of Postprandial Gastrointestinal Tract: Role of CCK and Sensory Pathways”; Annals of New York Academy of Science; pp. 143-156; 1994.
Renshaw et al. ‘Peptide YY: A Potential Therapy for Obesity’; Current Drug Targets; V. 6; pp. 171-179; 2005.
Sannino et al., ‘Crosslinking of Cellulose Derivatives and Hyaluronic Acid with Water-Soluble Carbodiimide,’ Polymer 46(2005)pp. 11206-11212.
Shechter et al.; “Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice”; FEBS Letters; V. 579; pp. 2439-2444; 2005.
Silver et al.; ‘Physical Properties of Hyaluronic Acid and Hydroxypropylmethylcellulose in Solution: Evaluation of Coating Ability’ Journal of Applied Biomaterials, V. 5; pp. 89-98, 1994.
Small et al.; ‘Gut hormones and the control of appetite’; TRENDS in Endocrinology and Metabolism; V. 15; No. 6; pp. 259-263; Aug. 2004.
Stanley et al.; ‘Gastrointestinal Satiety Signals III. Glucagon-like Peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide’; Am. J. Physiol Gastrointest Liver Physiol; V. 286; pp. 693-697; 2004.
Tezel, ‘The Science of Hyaluronic Acid Dermal Fillers,’ Journal of Cosmetic and Laser Therapy (2008) 10: pp. 35-42.
Tolhurst et al.; ‘Nutritional regulation of glucagon-like peptidel secretion’; J. Physiol.; V. 587, No. I;pp. 27-32; 2009.
Totte et al.; “Weight Reduction by Means of Intragastric Device: Experience with the Bioenterics Intragastric Balloon”, Obesity Surgery; V. 11, pp. 519-523; 2001.
Tough et al.; ‘Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa’; The Journal of Pharmacology and Experimental Therapeutics; V. 319, No. 1; pp. 20-30; 2006.
Tseng et al; “Peptide YY and cancer: Current findings and potential clinical applications”; Peptides; V. 23; pp. 389-395; 2002.
Valassi et al.; “Neuroendocrine control of food intake”; Nut. Metab. & Cariovasc. Disease; V. 18; pp. 158-168; 2008.
Van Der Lely et al.; “Biological, Physiological, Pathophysiological Aspects of Ghrelin”; Endocrine Reviews; V. 25, No. 3; pp. 426-457; 2004.
Verdich et al. ‘A Meta-Analysis of the Effect of Glucagon-Like-Peptide-1 (7-36) Amide on ad Libitum Energy Intake in Humans’; J. Clin. Endocrinal. Metab. V. 86; pp. 4382-4389; Sep. 2001.
Wahlen et al.; ‘The BioEnterics Intragastric Balloon (BIB): How to Use It’; Obesity Surgery; V. 11; pp. 524-527; 2001.
Wang et al.; “Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy”; Obes. Surg.; pp. 357-362; 2008.
Weiner et al.; ‘Preparation of Extremely Obese Patients for Laparoscopic Gastric Banding by Gastric Balloon Therapy’; Obesity Surgery; V. 9, pp. 261-264, 1999.
Wynne et al.; ‘Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subiects: A Double-Blind Randomized, Controlled Trial’: Diabetes; V. 54; pp. 2390-2395; 2005.
Yuzuriha et al.; “Gastrointestinal Hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development”; Faseb J.; V. 21; pp. 2108-2112; 2007.
Brown et al; ‘Symmetrical Pouch Dilation After Laparoscopic Adjustable Gastric Banding: Incidence and Management’; Obesity Surgery; V. 18, pp. 1104-1108; 2008.
Ceelen et al.; ‘Surgical Treatment of Severe Obesity With a Low-Pressure Adjustable Gastric Band: Experimental Data and Clinical Results in 625 Patients’; Annals of Surgery; V. 237, No. I;pp. 10-16; 2003.
Dixon et al.; ‘Pregnancy After Lap-Band Surgery: Management of the Band to Achieve Healthy Weight Outcomes’; Obesity Surgery; V. 11, pp. 59-65; 2001.
Neary et al.; ‘Peptide YY(3-36) and Glucagon-Like Peptide-1.sub.(7-36) Inhibit Food Intake Additively’; Endocrinology; V.146; pp. 5120-5127; 2005.
Padidela et al.; ‘Elevated basal and post-feed glucagon-like petide 1 (GLP-1) concentrations in the neonatel period’; European Journal of Endocrinology; v. 160; pp. 53-58; 2009.
Shi et al; ‘Sexually Dimorphic Responses to Fat Loss After Caloric Restriction or Surgical Lipectomy’; Am. J. Physiol. Endocrinol. Metab.; V. 293; E316-E326; 2007.
Xanthakos et al.; ‘Bariatric Surgery for Extreme Adolescent Obesity: Indications, Outcomes, and Physiologic Effects on the Gut-Brain Axis’; Pathophysiology; V. 15; pp. 135-146; 2008.
Related Publications (1)
Number Date Country
20130296644 A1 Nov 2013 US
Continuations (1)
Number Date Country
Parent 13049453 Mar 2011 US
Child 13934987 US
Continuation in Parts (1)
Number Date Country
Parent 12770617 Apr 2010 US
Child 13049453 US